Literature DB >> 16129847

Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.

Luca Agnelli1, Silvio Bicciato, Michela Mattioli, Sonia Fabris, Daniela Intini, Donata Verdelli, Luca Baldini, Fortunato Morabito, Vincenzo Callea, Luigia Lombardi, Antonino Neri.   

Abstract

PURPOSE: The deregulation of CCND1, CCND2 and CCND3 genes represents a common event in multiple myeloma (MM). A recently proposed classification grouped MM patients into five classes on the basis of their cyclin D expression profiles and the presence of the main translocations involving the immunoglobulin heavy chain locus (IGH) at 14q32. In this study, we provide a molecular characterization of the identified translocations/cyclins (TC) groups.
MATERIALS AND METHODS: The gene expression profiles of purified plasma cells from 50 MM cases were used to stratify the samples into the five TC classes and identify their transcriptional fingerprints. The cyclin D expression data were validated by means of real-time quantitative polymerase chain reaction analysis; fluorescence in situ hybridization was used to investigate the cyclin D loci arrangements, and to detect the main IGH translocations and the chromosome 13q deletion.
RESULTS: Class-prediction analysis identified 112 probe sets as characterizing the TC1, TC2, TC4 and TC5 groups, whereas the TC3 samples showed heterogeneous phenotypes and no marker genes. The TC2 group, which showed extra copies of the CCND1 locus and no IGH translocations or the chromosome 13q deletion, was characterized by the overexpression of genes involved in protein biosynthesis at the translational level. A meta-analysis of published data sets validated the identified gene expression signatures.
CONCLUSION: Our data contribute to the understanding of the molecular and biologic features of distinct MM subtypes. The identification of a distinctive gene expression pattern in TC2 patients may improve risk stratification and indicate novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16129847     DOI: 10.1200/JCO.2005.01.3870

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  42 in total

1.  Dynamism in gene expression across multiple studies.

Authors:  Alexander A Morgan; Joel T Dudley; Tarangini Deshpande; Atul J Butte
Journal:  Physiol Genomics       Date:  2009-11-17       Impact factor: 3.107

2.  MUC1-C drives MYC in multiple myeloma.

Authors:  Ashujit Tagde; Hasan Rajabi; Audrey Bouillez; Maroof Alam; Reddy Gali; Shannon Bailey; Yu-Tzu Tai; Teru Hideshima; Kenneth Anderson; David Avigan; Donald Kufe
Journal:  Blood       Date:  2016-02-23       Impact factor: 22.113

3.  Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.

Authors:  Shaji K Kumar; Hajime Uno; Susanna J Jacobus; Scott A Van Wier; Greg J Ahmann; Kimberly J Henderson; Natalie S Callander; Jessica L Haug; David S Siegel; Philip R Greipp; Rafael Fonseca; S Vincent Rajkumar
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

Review 4.  Reconstructing the evolutionary history of multiple myeloma.

Authors:  Francesco Maura; Even H Rustad; Eileen M Boyle; Gareth J Morgan
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-11       Impact factor: 3.020

5.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

6.  Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.

Authors:  Salomon Manier; Daisy Huynh; Yu J Shen; Jia Zhou; Timur Yusufzai; Karma Z Salem; Richard Y Ebright; Jiantao Shi; Jihye Park; Siobhan V Glavey; William G Devine; Chia-Jen Liu; Xavier Leleu; Bruno Quesnel; Catherine Roche-Lestienne; John K Snyder; Lauren E Brown; Nathanael Gray; James Bradner; Luke Whitesell; John A Porco; Irene M Ghobrial
Journal:  Sci Transl Med       Date:  2017-05-10       Impact factor: 17.956

7.  Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.

Authors:  Lucía López-Corral; Luis Antonio Corchete; María Eugenia Sarasquete; María Victoria Mateos; Ramón García-Sanz; Encarna Fermiñán; Juan-José Lahuerta; Joan Bladé; Albert Oriol; Ana Isabel Teruel; María Luz Martino; José Hernández; Jesús María Hernández-Rivas; Francisco Javier Burguillo; Jesús F San Miguel; Norma C Gutiérrez
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

8.  Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.

Authors:  Yoichi Imai; Eri Ohta; Shu Takeda; Satoko Sunamura; Mariko Ishibashi; Hideto Tamura; Yan-Hua Wang; Atsuko Deguchi; Junji Tanaka; Yoshiro Maru; Toshiko Motoji
Journal:  JCI Insight       Date:  2016-04-21

9.  Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia.

Authors:  Stefano Molica; Gaetano Vitelli; Giovanna Cutrona; Katia Todoerti; Rosanna Mirabelli; Giovanna Digiesi; Diana Giannarelli; Isabella Sperduti; Matteo Molica; Massimo Gentile; Fortunato Morabito; Antonino Neri; Manlio Ferrarini
Journal:  Int J Hematol       Date:  2008-09-27       Impact factor: 2.490

10.  Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.

Authors:  Ariel Anguiano; Sascha A Tuchman; Chaitanya Acharya; Kelly Salter; Cristina Gasparetto; Fenghuang Zhan; Madhav Dhodapkar; Joseph Nevins; Bart Barlogie; John D Shaughnessy; Anil Potti
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.